Adjunctive treatment with the urinary trypsin inhibitor ulinastatin does not appear to reduce mortality in patients with sepsis compared with placebo, according to the ADJUST trial.
ADJUST was a multicentre, randomized, double-blind, placebo-controlled trial. A total of 347 adult patients admitted to an ICU who met Sepsis-3 criteria were enrolled within 48 h of admission.
The patients were randomly assigned to receive intravenous ulinastatin 400,000 IU every 8 h or placebo for up to 10 days in addition to standard care.
The primary endpoint was all-cause mortality at 28 days. Secondary endpoints included ICU, hospital, and 90-day mortality and ICU/hospital length of stay.
Of the patients, 340 received the intervention, including 169 in the ulinastatin group and 171 in the placebo group, and were included in the analysis.
The rate of all-cause mortality at 28 days was 23.6 percent in the ulinastatin group vs 22.9 percent in the placebo group (absolute difference, 0.7 percent, 95 percent confidence interval [CI], –8.4 to 9.7; p=0.98). Ulinastatin had no significant effect on the primary endpoint compared with placebo (hazard ratio, 1.03, 95 percent CI, 0.66–1.61; p=0.90).
Similarly, secondary outcomes did not significantly differ between the two groups.
In terms of safety, adverse events occurred more frequently in the ulinastatin vs the placebo group (56.8 percent vs 42.7 percent; absolute difference, 14.1 percent, 95 percent CI, 3.6–24.6; p=0.009).
The findings do not support routine use of ulinastatin for sepsis.